Skip to main content
. Author manuscript; available in PMC: 2021 Aug 26.
Published in final edited form as: ACS Infect Dis. 2020 Nov 25;6(12):3224–3236. doi: 10.1021/acsinfecdis.0c00599

Figure 2.

Figure 2.

RD25 for EcClpP and NmClpP. (A) RD25 values were measured for EcClpP and NmClpP in the presence of 85 different ACP1 analogues. The “x” indicates five compounds that were not investigated due to compound purity issues. (B) RD25 values were measured for EcClpP and NmClpP in the presence of 46 different ADEP analogues. The compounds are numbered according to their relative activity on NmClpP, with ACP1-01 and ADEP-01 being the most active analogues and are listed in the same order in the top (EcClpP) and bottom (NmClpP) panels. Compounds highlighted in red are discussed in Figure 3.